Core Insights - Tempus AI, Inc. has launched a new AI-powered cancer diagnostic algorithm, the Pan-Cancer HRD-RNA algorithm, which utilizes RNA analysis to identify Homologous Recombination Deficiency, enhancing the identification of patients likely to respond to specific chemotherapy treatments [3][9] - The company's stock has seen a 6.86% increase over the past week, currently trading at $57.29, although it remains down 18.54% over the past month [2][6] - Preliminary Q4 results indicate a revenue of $367 million, representing an 83% year-over-year increase, with a total contract value exceeding $1.1 billion [4][9] - Analysts maintain a bullish outlook with a consensus target price of $85.69, suggesting nearly 50% upside potential from current stock levels [5][9] Company Developments - The HRD-RNA algorithm is currently available for research use, with clinical availability anticipated later in 2026, indicating ongoing innovation within the company's AI-driven diagnostics platform [3][6] - Key items to monitor in the upcoming earnings report include detailed financials, commentary on the path to profitability, and guidance for 2026 [4] Market Sentiment - Wall Street analysts have issued 2 Strong Buy and 5 Buy ratings for Tempus, reflecting confidence in the company's accelerating revenue growth and expanding diagnostic capabilities [5]